UniProtKB/Swiss-Prot Q9Y6X9: Variant p.Ser87Leu

• Variant information
• Sequence information
• Literature citations
• All

Variant information

Variant position: 87 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: LP/P [Disclaimer: Variants classification is intended for research purposes only, not for clinical and diagnostic use. The label disease variant is assigned according to literature reports on probable disease-association that can be based on theoretical reasons. This label must not be considered as a definitive proof for the pathogenic role of a variant.] The variants are classified into three categories: LP/P, LB/B and US.

• LP/P: likely pathogenic or pathogenic.
• LB/B: likely benign or benign.
• US: uncertain significance

Residue change: From Serine (S) to Leucine (L) at position 87 (S87L, p.Ser87Leu). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: Change from small size and polar (S) to medium size and hydrophobic (L) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

• Lowest score: -4 (low probability of substitution).
• Highest score: 11 (high probability of substitution).

More information can be found on the following page
Variant description: In CMT2Z and DIGFAN; decreased ATPase activity; ATP-independent homodimerization; increases HUSH-dependent gene silencing. Any additional useful information about the variant.
Other resources: Links to websites of interest for the variant.

• Variant rs864309504 [ dbSNP | Ensembl ]

Sequence information

Variant position: 87 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 1032 The length of the canonical sequence.
Location on the sequence: LDDGAGMDPSDAASVIQFGK S AKRTPESTQIGQYGNGLKSG The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

• Type: the type of sequence feature.
• Positions: endpoints of the sequence feature.
• Description: contains additional information about the feature.

Type	Positions	Description
Chain	2 – 1032	ATPase MORC2
Binding site	87 – 89
Mutagenesis	68 – 68	D -> A. Loss of ATP-binding and ATPase activity. Loss of binding to ATP and ATPase activity; when associated with A-69. Prevents chromatin remodeling.
Mutagenesis	69 – 69	D -> A. No effect on binding to ATP and ATPase activity; when associated with A-68.

Literature citations

Mutations in the MORC2 gene cause axonal Charcot-Marie-Tooth disease.
Sevilla T.; Lupo V.; Martinez-Rubio D.; Sancho P.; Sivera R.; Chumillas M.J.; Garcia-Romero M.; Pascual-Pascual S.I.; Muelas N.; Dopazo J.; Vilchez J.J.; Palau F.; Espinos C.;
Brain 139:62-72(2016)
Cited for: VARIANTS CMT2Z LEU-87 AND TRP-252; De Novo Variants in the ATPase Module of MORC2 Cause a Neurodevelopmental Disorder with Growth Retardation and Variable Craniofacial Dysmorphism.
Guillen Sacoto M.J.; Tchasovnikarova I.A.; Torti E.; Forster C.; Andrew E.H.; Anselm I.; Baranano K.W.; Briere L.C.; Cohen J.S.; Craigen W.J.; Cytrynbaum C.; Ekhilevitch N.; Elrick M.J.; Fatemi A.; Fraser J.L.; Gallagher R.C.; Guerin A.; Haynes D.; High F.A.; Inglese C.N.; Kiss C.; Koenig M.K.; Krier J.; Lindstrom K.; Marble M.; Meddaugh H.; Moran E.S.; Morel C.F.; Mu W.; Muller E.A. II; Nance J.; Natowicz M.R.; Numis A.L.; Ostrem B.; Pappas J.; Stafstrom C.E.; Streff H.; Sweetser D.A.; Szybowska M.; Walker M.A.; Wang W.; Weiss K.; Weksberg R.; Wheeler P.G.; Yoon G.; Kingston R.E.; Juusola J.;
Am. J. Hum. Genet. 107:352-363(2020)
Cited for: INVOLVEMENT IN DIGFAN; VARIANTS DIGFAN ILE-24; LYS-27; LEU-87; VAL-88; CYS-132; SER-266; ARG-388; CYS-394 AND PHE-413; CHARACTERIZATION OF VARIANTS DIGFAN ILE-24; LYS-27; LEU-87; CYS-132; SER-266; CHARACTERIZATION OF VARIANTS CMT2Z GLY-236; TRP-252; FUNCTION; Neuropathic MORC2 mutations perturb GHKL ATPase dimerization dynamics and epigenetic silencing by multiple structural mechanisms.
Douse C.H.; Bloor S.; Liu Y.; Shamin M.; Tchasovnikarova I.A.; Timms R.T.; Lehner P.J.; Modis Y.;
Nat. Commun. 9:651-651(2018)
Cited for: X-RAY CRYSTALLOGRAPHY (1.81 ANGSTROMS) OF 1-603 OF WILD-TYPE; X-RAY CRYSTALLOGRAPHY (1.81 ANGSTROMS) OF 1-603 OF; X-RAY CRYSTALLOGRAPHY (1.81 ANGSTROMS) OF 1-603 OF VARIANT CMT2Z LEU-87; X-RAY CRYSTALLOGRAPHY (1.81 ANGSTROMS) OF 1-603 OF VARIANT ARG-424 IN COMPLEX WITH ATP; MAGNESIUM AND ZINC; CHARACTERIZATION OF VARIANTS CMT2Z LEU-87 AND TRP-252; CHARACTERIZATION OF VARIANT ARG-424; FUNCTION; CATALYTIC ACTIVITY; SUBUNIT; MUTAGENESIS OF TYR-18; ASN-39; ARG-266; ARG-319; ARG-326; ARG-329; ARG-333; ARG-344; ARG-351 AND ARG-358;